Overview

A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

Status:
Completed

Trial end date:
2004-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase I, double blind, randomized, placebo-controlled study that will enroll approximately 50 adult subjects with Type 1 or Type 2 diabetes mellitus and chronic, diabetic foot ulcers. The study will be conducted at approximately 12 investigational sites in the United States.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab
Endothelial Growth Factors
Mitogens